International Healthcare Media, LLC Secures Strategic Alliances with Five Leading Medical Organizations
The partnerships will serve to bolster IHM’s mission of helping clinicians deliver quality care, improve patient outcomes and satisfaction, and optimize quality along the continuum of care.
Clinton, NJ (October 23, 2020) – International Healthcare Media, LLC (IHM), a global media communications company that engages healthcare professionals and patients through print media, live conferences, social media, and a robust digital platform, announced today that it has developed strategic alliances with five esteemed medical organizations.
Four of the partnerships are designed to help ophthalmologists improve patient outcomes through broad distribution of content on IHM’s Ophthalmology360® platform. Launched in 2018, Ophthalmology360® is a time-saving digital platform for the ophthalmic community, providing timely and relevant summaries of important studies, critical coverage of top national and international eye care meetings, and best practices from the country’s leading ophthalmic surgeons. The website is a hub that keeps clinicians abreast of the latest and most relevant clinical, practice management, marketing, and legislative news, as well as patient education and other important developments impacting eye care.
The alliances are with the American Macular Degeneration Foundation, Foundation Fighting Blindness, Glaucoma Research Foundation, and Women in Ophthalmology. The partnerships will help both Ophthalmology360® and these organizations meet the important clinical and research needs of their audiences. Ophthalmology360® will provide coverage of important conferences hosted by Women in Ophthalmology and will be a key marketing partner with the society. Specialists from the Foundation Fighting Blindness will contribute expertise and analysis on important topics such as emerging therapies and inherited retinal degenerations.
The fourth partnership is between Rare Disease 360®, IHM’s rare disease platform, and World Orphan Drug Congress. Rare Disease 360® is an all-encompassing resource hub that compiles the entirety of relevant information on multiple rare disease states to help health care professionals make the biggest impact on some of the smallest patient populations. The Rare Disease 360® and World Orphan Drug alliance will lead to wider coverage of the orphan drug group’s conferences, and thus broader dissemination of important information in the high need area of rare diseases.
Christopher Ciraulo, IHM’s President & CEO, states, “These strategic alliances demonstrate our commitment to content creation, development, and dissemination in two important areas of medicine. Joining IHM’s clinical content platforms — which have gained traction and credibility in record time – with organizations that have stellar reputations and are among medicine’s elite, enables us to fulfill our mission of helping clinicians deliver quality care, improve patient outcomes and satisfaction, and optimize quality along the continuum of care.”
Matthew Marano, MD, Chief Medical Editor, says these partnerships “enhance the entire IHM platform and continues to offer its community a treasure trove of late-breaking content.” The partnerships extend the overall reach, adds instantaneous brand credibility, and assists health care professionals in improving quality of care and patient outcomes. Moreover, it exemplifies the IHM corporate tagline, “All content Should Be This Good®.”
About International Health Care Media, LLC
International Healthcare Media is a global communications media company that engages healthcare professionals and patients via live congresses, print brands, video, and proprietary digital media assets. IHM helps clinicians deliver quality care, improve patient outcomes and satisfaction, and optimize quality along the continuum of care through brands that target specific clinicians, diseases, and conditions. Using its international reach and access to key thought leaders around the globe, IHM delivers an audience of engaged healthcare professionals by providing clinicians with succinct practical recommendations.
To learn more about International Healthcare Media, visit ihmholdings.com
About the American Macular Degeneration Foundation
AMDF is a patient-centered foundation that supports potentially game-changing Age-related macular degeneration (AMD) research, education, and advocacy in order to improve quality of life and treatment outcomes for all those affected by AMD (macular.org).
About the Foundation Fighting Blindness
Established in 1971, the Foundation Fighting Blindness is the world’s leading private funding source for retinal degenerative disease research. The Foundation has raised more than $800 million toward its mission of accelerating research for preventing, treating, and curing blindness caused by the entire spectrum of retinal degenerative diseases including: retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and Stargardt disease. Visit FightingBlindness.org for more information.
About the Glaucoma Research Foundation
Glaucoma Research Foundation (GRF) is a national non-profit organization dedicated to finding a cure for glaucoma. For more than 40 years, Glaucoma Research Foundation has worked to advance sight-saving research and provide essential educational resources for patients. It funds critical research into glaucoma treatment, vision restoration, and a cure for glaucoma. It is also the leading source of information for glaucoma patients and their families. For more information, visit www.glaucoma.org.
About Women In Ophthalmology
Women In Ophthalmology, Inc. was founded to enhance and improve the professional environment for women ophthalmologists. We encourage diversity, impartiality, and economic parity, and strive to cultivate new opportunities for leadership, education, and public service in the field of ophthalmology for ourselves and future generations, both nationally and internationally.
About World Orphan Drug Congress USA
World Orphan Drug Congress USA is the largest global industry gathering for the orphan drug industry and rare disease community where pharma, biotech, patient groups, academia, regulators, payers and investors gather.